Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–2 of 2 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
Interventions
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + dabrafenib (Treatment Group D), IMM-1-104 + pembrolizumab (Treatment Group E)
Drug
Lead sponsor
Immuneering Corporation
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Scottsdale, Arizona • Duarte, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced May 22, 2026, 1:37 AM EDT
Conditions
NRAS Mutation, NRAS-mutant Advanced Melanoma, NRAS-mutant Solid Tumors, NRAS Q61R, NRAS Q61K, NRAS Q61L, NRAS Q61H, NRAS G12D, NRAS G13R, NRAS G13D, NRAS G12V
Interventions
RLY-8161
Drug
Lead sponsor
Relay Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Boston, Massachusetts • Grand Rapids, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 22, 2026, 1:37 AM EDT